Bladder Cancer

Low or Intermediate risk NMIBC

Vaxiion– Phase I Safety and Tolerability of Intravesical VAX014 for Instillation in Subjects with Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase: 1
Study Product: Intravesical VAX014 
Estimated Study Completion Date: 
ClinicalTrials.gov Identifier: NCT03854721

High grade NMIBC BCG Naïve or no BCG within 2 years

Pfizer b8011006: Study of PF-06801591 in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer.

Phase: 3
Study Product: PF-06801591 in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) vs. BCG (Induction and Maintenance)
Estimated Study Completion Date: December 9, 2026
ClinicalTrials.gov Identifier: NCT04165317

High Grade NMIBC Post BCG

KEYNOTE-676: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in HR NMIBC

Phase: 3
Study Product: Pembrolizumab with BCG
Estimated Study Completion Date: November 25, 2024
ClinicalTrials.gov Identifier: NCT03711032

KEYNOTE-057: Study of Pembrolizumab (MK-3475) in Participants With HR NMIBC

Phase: 2
Study Product: Pembrolizumab
Estimated Study Completion Date: July 30, 2023
ClinicalTrials.gov Identifier: NCT02625961

CheckMate 9UT: A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without BCG in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Phase: 2
Study Product: Nivolumab vs. Nivolumab with BCG vs. Nivolumab with BMS-986205 vs. Nivolumab with BMS-986205 with BCG
Estimated Study Completion Date: April 16, 2023
ClinicalTrials.gov Identifier: NCT03519256

MIBC

Bladder Sparing

NanoDoce: Evaluation of NanoDoce in Subjects with Urothelial Carcinoma

Phase: 1/2
Study Product: NanoDoce Injection with NanoDoce Intravesical Instillation vs. NanoDoce Injection with Standard of Care
Estimated Study Completion Date: November 2020
ClinicalTrials.gov Identifier: NCT03636256

KEYNOTE-992: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Phase: 3
Study Product: Pembrolizumab with Chemoradiotherapy (CRT) vs. CRT Alone
Estimated Study Completion Date: February 10, 2027
ClinicalTrials.gov Identifier: NCT04241185

Radical Cystectomy

KEYNOTE-905: Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer

Phase: 3
Study Product: Pembrolizumab with Radical Cystectomy plus Pelvic Lymph Node Dissection vs. Radical Cystectomy plus Pelvic Lymph Node Dissection
Estimated Study Completion Date: February 16, 2026
ClinicalTrials.gov Identifier: NCT03924895

Seattle Genetics EV-103: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Phase: 1b/2
Study Product: neoadjuvant therapy followed by Radical Cystectomy for cis-ineligible MIBC – Cohort H: Enfortumab vedotin (EV), Cohort J: EV + Pembrolizumab
Estimated Study Completion Date: March 2026
ClinicalTrials.gov Identifier: NCT03288545

Locally Advanced or Metastatic UC

Seattle Genetics EV-103: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Phase: 1b/2
Study Product: Cohort K: Enfortumab vedotin (EV) alone vs EV + Pembrolizumab for cis-ineligible patients 
Estimated Study Completion Date: March 2026
ClinicalTrials.gov Identifier: NCT03288545